Praxis (PRAX) Director Converts Options into 17,251 Shares on 09/24/2025

Rhea-AI Filing Summary

Mitchell Dean J, a director of Praxis Precision Medicines, Inc. (PRAX), reported multiple option exercises and resulting share holdings on 09/24/2025. He acquired 1,932 shares via exercise at $14.36, 8,566 shares at $44.25 and 1,753 shares at $44.04, increasing his direct beneficial ownership to 17,251 shares. The related options have varying vesting histories: the $14.36 option fully vested 06/12/2024, the $44.25 option fully vested 06/05/2025, and the $44.04 option vests monthly over one year starting 06/26/2025. The reported transactions were filed by an attorney-in-fact on 09/25/2025.

Positive

• Director increased direct ownership to 17,251 shares following option exercises, showing insider accumulation
• Clear vesting disclosures provided: two options fully vested (06/12/2024 and 06/05/2025) and one vests monthly over one year starting 06/26/2025
• Timely Section 16 reporting filed (Form 4) and signed by attorney-in-fact, indicating compliance with disclosure rules

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider option exercises increased a director's direct stake but appear non-dilutive and consistent with prior vesting schedules.

The Form 4 shows director exercises of three stock options at exercise prices of $14.36, $44.25 and $44.04, converting into 17,251 directly held shares after the transactions. Two options were already fully vested and one vests over 12 months, indicating these are largely scheduled compensation events rather than opportunistic trades. There is no disclosure of open-market sales or change in control items. For investors, this filing documents insider accumulation via standard equity compensation mechanisms but does not, by itself, alter company fundamentals.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting; vesting and exercise timing appear compliant and routine.

The filing documents timely Section 16 reporting of option exercises and resulting direct ownership by a director. The explanation clarifies vesting dates, including one grant that vests in monthly installments beginning 06/26/2025. The signature by an attorney-in-fact is properly noted. There are no indications of related-party transactions, accelerated vesting, or changes to control provisions disclosed here. Governance implications are minimal and reflect standard executive equity administration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MITCHELL DEAN J

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2025		M		1,932	A	$14.36	6,932	D
Common Stock	09/24/2025		M		8,566	A	$44.25	15,498	D
Common Stock	09/24/2025		M		1,753	A	$44.04	17,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.36	09/24/2025		M			1,932	(1)	06/12/2033	Common Stock	1,932	$0	0	D
Stock Option (Right to Buy)	$44.25	09/24/2025		M			8,566	(2)	06/05/2034	Common Stock	8,566	$0	0	D
Stock Option (Right to Buy)	$44.04	09/24/2025		M			1,753	(3)	06/26/2035	Common Stock	1,753	$0	8,767	D

Explanation of Responses:

1. This option was fully vested as of June 12, 2024.

2. This option was fully vested as of June 5, 2025.

3. The shares subject to this option vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mitchell Dean J report on the Form 4 for PRAX?

The filing reports exercises of three stock options on 09/24/2025 resulting in 17,251 directly held shares after the transactions.

What were the exercise prices and amounts exercised in the PRAX Form 4?

Exercises were 1,932 shares at $14.36, 8,566 shares at $44.25, and 1,753 shares at $44.04.

Which options were already vested according to the filing?

The $14.36 option was fully vested on 06/12/2024 and the $44.25 option was fully vested on 06/05/2025.

What is the vesting schedule for the remaining option disclosed?

The $44.04 option vests in twelve equal monthly installments over one year beginning on 06/26/2025.

Was the Form 4 signed by the reporting person?

The filing shows it was signed by Alex Nemiroff, as Attorney-in-Fact on 09/25/2025 on behalf of the reporting person.